Literature DB >> 10918303

Roles of BRCA1 and its interacting proteins.

C X Deng1, S G Brodie.   

Abstract

Germline mutations of BRCA1 predispose women to breast and ovarian cancers. BRCA1 contains several functional domains that interact directly or indirectly with a variety of molecules, including tumor suppressors (p53, RB, BRCA2 and ATM), oncogenes (c-Myc, casein kinase II and E2F), DNA damage repair proteins (RAD50 and RAD51), cell-cycle regulators (cyclins and cyclin-dependent kinases), transcriptional activators and repressors (RNA polymerase II, RHA, histone deacetylase complex and CtIP) and others. Mounting evidence indicates that these physical associations are not artifacts; rather, BRCA1 is likely to serve as an important central component in multiple biological pathways that regulate cell-cycle progression, centrosome duplication, DNA damage repair, cell growth and apoptosis, and transcriptional activation and repression. This review examines our understanding of the significance of the interactions between BRCA1 and other proteins, through which BRCA1 maintains genome integrity and represses tumor formation. Published 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10918303     DOI: 10.1002/1521-1878(200008)22:8<728::AID-BIES6>3.0.CO;2-B

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  93 in total

1.  Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains.

Authors:  Donna L Mallery; Cassandra J Vandenberg; Kevin Hiom
Journal:  EMBO J       Date:  2002-12-16       Impact factor: 11.598

2.  Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex.

Authors:  Peter S Brzovic; Jennifer R Keeffe; Hiroyuki Nishikawa; Keiko Miyamoto; David Fox; Mamoru Fukuda; Tomohiko Ohta; Rachel Klevit
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

3.  A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein.

Authors:  Nicolas Foray; Didier Marot; Anastasia Gabriel; Voahangy Randrianarison; Antony M Carr; Michel Perricaudet; Alan Ashworth; Penny Jeggo
Journal:  EMBO J       Date:  2003-06-02       Impact factor: 11.598

4.  Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform.

Authors:  Liu Cao; Wenmei Li; Sangsoo Kim; Steven G Brodie; Chu-Xia Deng
Journal:  Genes Dev       Date:  2003-01-15       Impact factor: 11.361

5.  DNA damage response mediated through BRCA1.

Authors:  Eun Ryoung Jang; Jong-Soo Lee
Journal:  Cancer Res Treat       Date:  2004-08-31       Impact factor: 4.679

Review 6.  Fine tuning chemotherapy to match BRCA1 status.

Authors:  Melissa Price; Alvaro N A Monteiro
Journal:  Biochem Pharmacol       Date:  2010-05-25       Impact factor: 5.858

7.  Molecular cytogenetics of mouse models of breast cancer.

Authors:  Thomas Ried; Kathy Dorritie; Zoë Weaver; Danny Wangsa; Michael J Difilippantonio; Cristina Montagna
Journal:  Breast Dis       Date:  2004

8.  Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1.

Authors:  Sang Soo Kim; Liu Cao; Cuiling Li; Xiaoling Xu; L Julie Huber; Lewis A Chodosh; Chu-Xia Deng
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

9.  The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.

Authors:  Ciric To; Eun-Hee Kim; Darlene B Royce; Charlotte R Williams; Ryan M Collins; Renee Risingsong; Michael B Sporn; Karen T Liby
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-09

10.  Association of loss of BRCA1 expression with centrosome aberration in human breast cancer.

Authors:  Atsushi Shimomura; Yasuo Miyoshi; Tetsuya Taguchi; Yasuhiro Tamaki; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-24       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.